John W. Smither joined eFFECTOR’s board of directors in March 2018. Previously, Mr. Smither most recently served as the interim chief financial officer of Kite Pharma, a Gilead Company from November 2017 through April 2018, and was the chief financial officer of Unity Biotechnology and Sienna Biopharmaceuticals, which he rejoined in April 2018. He also served as chief financial officer at Kythera Biopharmaceuticals, where he was responsible for all financial activities during early clinical stage through approval and launch, led private fundraising rounds, prepared the company for its successful initial public offering in October 2012, and oversaw its acquisition by Allergan for approximately $2.1 billion. At Amgen, he held several financial positions of increasing responsibility, including vice president of finance and administration for Amgen’s European operations in 28 countries, and having served most recently as Executive Director, Corporate Accounting. Since 2013, Mr. Smither has served as member of the board of directors of Achaogen, Inc., and is chair of the audit and member of the compensation committees. Mr. Smither began his career at Ernst & Young where he was audit partner and held certification as a Certified Public Accountant (inactive). He holds a B.S. in accounting, with honors, from California State University at Los Angeles.